Bipolar catheter ablation for highly refractory cardiac arrhythmia—does rate of success depend on arrhythmia origin?

Progressive decline across periods in mortality rates among patients with implantable cardioverter-defibrillator (ICD). Chagas disease (ChD) was associated with increased rates of ventricular tachycardia and ventricular fibrillation in ICD patients only in the initial two periods, but there was no statistical difference in the last period.

Patients with Brugada syndrome who are asymptomatic and have no ventricular tachycardia/ventricular fibrillation inducibility by programmed electrical stimulation are at extremely low risk of experiencing late life-threatening arrhythmias.

Long-term Follow-up of Patients with Brugada Syndrome from a Tertiary Referral Center in Iran

Pulsed electric field (PEF) ablation with a specialized large area focal catheter in a swine model is dependent on catheter–tissue contact. Local impedance can be used as an indicator of catheter–tissue contact and aid in the creation of consistent transmural lesions in PEF ablation.

In patients with atrial fibrillation (AF) ablation and diabetes mellitus (DM), the prevalence of left atrial low-voltage areas (LVAs) increased with increasing glycated hemoglobin A1c (HbA1c) level. In patients with LVAs, freedom from AF recurrence was lower in patients who had DM with HbA1c ≥7% than in those without DM.

The impact of supraventricular arrhythmias on the outcomes of guideline-compliance implantable cardioverter defibrillators programming.

The study flow and main findings in the present subanalysis of the Mt FUJI trial. AVB, atrioventricular block; JTc, corrected JT interval; QTc, corrected QT interval; RAO, right anterior oblique view; RVS, right ventricular septum.

Intrinsic antitachycardia pacing (iATP) may be beneficial both as first-line and secondary therapies to terminate ventricular tachycardia (VT) effectively in comparison with conventional antitachycardia pacing (ATP). Our preliminary results highlight the unique algorithm of electrical-based, individual ATP and its possible benefit in terminating VT, which has future prospects for improving the prognosis of implantable cardioverter-defibrillator recipients.

This novel cryoballoon with adjustable size and low compliance successfully achieves pulmonary vein isolation to treat paroxysmal atrial fibrillation (PAF), providing more options for patients with PAF. This cryoballoon system was proven to be safe and effective for treatment of patients with drug refractory or drug intolerant PAF.